Clinical Guides
Oral Cancer
A clinically focused guide to recognising and coordinating oral-cavity cancer care in India, covering high-risk lesions, biopsy, anatomical staging, definitive treatment, rehabilitation and the limits of applying foreign pathways locally.
MedNext Academy | 14 min read
Oral Cancer
A clinically focused guide to recognising and coordinating oral-cavity cancer care in India, covering high-risk lesions, biopsy, anatomical staging, definitive treatment, rehabilitation and the limits of applying foreign pathways locally.
Summary
Oral cancer in this guide means malignancy arising in the lip mucosa, anterior two-thirds of tongue, floor of mouth, buccal mucosa, upper or lower gingiva, retromolar trigone or hard palate. Most invasive tumours are squamous cell carcinomas, but salivary, melanocytic and other neoplasms occur. Oral cavity and oropharynx are anatomically and biologically distinct: a tonsillar or tongue-base tumour is not simply an oral-cavity cancer, and HPV-associated staging must not be transferred to an anterior tongue lesion. Potentially malignant disorders, including leukoplakia, erythroplakia and oral submucous fibrosis, are not synonymous with invasive cancer; some contain dysplasia and require risk-stratified surveillance or treatment.
A non-healing ulcer, induration, unexplained oral lump, persistent red or mixed red-white patch, reduced tongue movement, trismus or cervical node warrants structured assessment. Visual inspection alone cannot determine histology. Diagnosis requires representative biopsy, while imaging defines local extension, nodal disease and distant spread when appropriate. Primary-site dimensions, depth of invasion, adjacent-structure involvement and extranodal extension influence staging and treatment.
Management is multidisciplinary and commonly surgery-led for resectable oral-cavity disease, with planned management of the neck and postoperative radiotherapy or chemoradiotherapy for selected adverse pathological features. Reconstruction, dental preparation, nutrition, speech and swallowing support, tobacco and areca-nut cessation, pain control and survivorship care are integral. international and NCI sources describe UK and US evidence frameworks; they cannot determine an Indian patient's regimen, financing pathway or available technique. This quarantined educational draft has been reviewed by the MedNext Clinical Team and is not a diagnostic or prescribing service.
How Common Is It?
Oral cancer is a major Indian health problem, but every figure must be anchored to a site definition, sex, year and estimation method. The IARC Global Cancer Observatory India fact sheet for GLOBOCAN 2024 lists lip and oral cavity among India's leading cancer sites, with a greater burden in men than women. The fact sheet contains modelled national estimates derived from cancer-registry data and demographic methods; it is not a complete enumeration of every diagnosis. Oral cavity, oropharynx, hypopharynx and larynx are reported separately, so adding or comparing figures without checking categories creates misleading totals.
Burden varies sharply within India. Tobacco form, areca-nut and betel-quid use, alcohol exposure, occupation, socioeconomic conditions, sex distribution, awareness, access to dentistry, registry coverage and distance from diagnostic services differ by state and community. A high population burden strengthens the case for prevention and prompt assessment, but it does not make every ulcer malignant. Conversely, young age, no smoking history or absence of pain cannot safely exclude cancer.
The National Health Mission operational framework places oral-cancer risk assessment and screening within comprehensive primary care and describes population screening for adults aged over 30 years in its programme. Screening is a public-health activity, not a biopsy result. Its effectiveness depends on examiner training, referral completion, pathology capacity and treatment access. Incidence, mortality and five-year prevalence answer different questions and should not be interchanged. For an individual patient, stage, subsite, depth of invasion, nodal status, pathological features, fitness and completion of treatment are more useful than a national average for discussing prognosis.
Risk Factors
Tobacco exposure is central to oral-cavity cancer prevention in India. History must distinguish cigarettes and bidis from smokeless products such as gutka, khaini, zarda and mishri, and should document frequency, duration, placement site and previous use. Areca nut is carcinogenic whether chewed alone or within betel quid; adding tobacco compounds risk but tobacco-free preparations are not safe. Alcohol is an independent risk and can act synergistically with tobacco. Patients should receive non-judgemental cessation support because dependence, commercial marketing and social practice influence exposure. Blame is clinically harmful and does not improve adherence.
Other considerations include previous head-and-neck cancer, chronic immunosuppression, prior radiotherapy, ultraviolet exposure for external lip cancer and poor nutritional or dental status. Persistent trauma may draw attention to a lesion but should not be casually labelled as the cause of a cancer. Oral submucous fibrosis, erythroplakia, proliferative verrucous leukoplakia and dysplastic oral lesions carry differing malignant potential. A white patch is a clinical description rather than a single diagnosis; risk depends on site, texture, homogeneity, size, histology and change over time.
HPV is strongly relevant to many oropharyngeal cancers but is not a universal explanation for oral-cavity squamous carcinoma. Confusing anterior tongue with tongue base can produce incorrect counselling and staging. Risk assessment should also anticipate treatment: dentition, weight loss, aspiration, renal function, hearing, neuropathy, cardiovascular disease, frailty and social support may alter feasibility. Prevention includes stopping all tobacco and areca products, moderating alcohol, maintaining oral health and attending review of a potentially malignant disorder; no supplement, mouthwash or home examination guarantees prevention.
Diagnosis
History
Establish the exact oral subsite, onset and progression. Ask about an ulcer, red or white patch, exophytic growth, bleeding, pain, referred otalgia, loose tooth, altered denture fit, dysarthria, dysphagia, odynophagia, drooling, trismus, tongue restriction, lower-lip or chin numbness and neck swelling. Record weight and dietary change. Document smoked and smokeless tobacco, areca or betel use, alcohol, prior lesions, biopsies, head-and-neck cancer, radiotherapy, immunosuppression, medicines and comorbidity. Clarify symptom treatments already tried; transient improvement after antibiotics does not exclude cancer.
Examination
Use adequate light, mirrors or tongue control, consent and infection precautions. Inspect and palpate every oral subsite, not only the reported lesion. Record surface, colour, ulcer edge, induration, fixation, bleeding, anatomical extent and relation to teeth or mandible. Assess tongue protrusion and mobility, mouth opening, cranial-nerve findings, dentition, nutrition and airway. Palpate cervical nodal levels bilaterally, describing size, mobility and skin involvement. Examine the oropharynx and consider flexible endoscopy through an appropriate specialist when another upper-aerodigestive lesion is possible.
Investigations
Arrange representative incisional or excisional biopsy through a service able to plan definitive care; avoid poorly placed sampling that compromises later resection. Histology should identify tumour type, differentiation and relevant pathological features. Contrast-enhanced CT or MRI is selected for deep soft-tissue, bone and nodal assessment; ultrasound-guided fine-needle aspiration or core biopsy can assess a suspicious neck node. Chest or systemic staging depends on clinical stage, and international guidelines advises systemic staging beyond early T1N0 or T2N0 upper-aerodigestive disease. Dental imaging, nutritional assessment and anaesthetic evaluation prepare treatment. Imaging cannot replace tissue, and a negative superficial biopsy needs reconciliation when clinical suspicion persists.
Differential Diagnosis
A traumatic ulcer from a sharp tooth, biting or an ill-fitting denture is common, but a plausible irritant does not end assessment. Remove the cause and document healing; persistence, induration or progression requires biopsy or urgent specialist review. Recurrent aphthous ulceration is usually episodic and non-indurated. Oral lichen planus, lichenoid drug reactions, candidiasis, discoid lupus and autoimmune blistering disease may produce erosive, white or red lesions. Tuberculosis, deep fungal infection and syphilis are less common mimics whose likelihood depends on immune status, exposure and systemic features. Empirical treatment without a defined review point can delay cancer diagnosis.
Leukoplakia, erythroplakia, erythroleukoplakia and oral submucous fibrosis are important because they may contain dysplasia or coexist with carcinoma. They require description, risk-factor assessment and histological strategy rather than reassurance based on colour. Verrucous carcinoma can appear slow-growing and deceptively bland; sampling must be deep and representative. Minor salivary-gland tumours may present as a palatal or submucosal mass. Pigmented lesions include benign melanosis, amalgam tattoo and oral melanoma. Necrotising sialometaplasia can mimic a palatal cancer clinically and histologically.
Dental abscess, periodontal disease, osteomyelitis and medication-related osteonecrosis can cause pain, swelling, ulceration or exposed bone. A metastatic deposit, lymphoma or primary bone malignancy is less frequent but changes the biopsy and staging pathway. The key reasoning task is not to memorise a long list: it is to recognise discordance. A lesion that is unexplained, persists beyond expected healing, feels indurated, causes progressive functional loss or is accompanied by a neck node should be treated as potentially malignant until adequately assessed.
Management
A head-and-neck multidisciplinary team should integrate oral and maxillofacial or head-and-neck surgery, radiation and medical oncology, pathology, radiology, restorative dentistry, anaesthesia, nutrition, speech and swallowing therapy, rehabilitation and palliative care. The plan is based on subsite, TNM stage, depth of invasion, nodal risk, pathological margins, extranodal extension, comorbidity, function and informed preference. For many resectable oral-cavity squamous cancers, surgery is the primary modality. Resection must address gross and microscopic extent while preserving function where oncologically safe; reconstruction may use local, regional or free tissue.
The clinically negative neck still requires active planning. Current guidelines recommends surgical management of the neck for T1-T2 N0 oral-cavity cancer and allows sentinel-node biopsy instead of elective dissection in selected early disease unless cervical access is otherwise required. Clinically involved nodes generally require therapeutic neck management. Postoperative radiotherapy is considered for adverse features such as advanced local stage, nodal burden, close margins, perineural or lymphovascular invasion; concurrent systemic radiosensitisation may be indicated for high-risk pathology such as a positive margin or extranodal extension, subject to fitness and protocol. Unresectable, metastatic or recurrent disease needs individual systemic, radiation, salvage or symptom-focused planning.
Before treatment, optimise nutrition, dentition, airway, analgesia and cessation support, and discuss speech, swallowing, appearance and work. Rehabilitation begins before resection or radiotherapy, not after disability is established. Foreign guideline choices depend on specialist concentration, pathology standards and funded technologies that may differ across Indian centres. Local tumour-board policy, current drug approval, affordability and expertise therefore govern the actual regimen. Early palliative-care involvement can control symptoms alongside anticancer treatment and does not mean abandonment.
Prescribing Information
There is no safe generic oral-cancer prescription. Medicines are selected by a specialist after histology, stage, prior treatment, organ function, performance status and treatment intent are known. Concurrent cisplatin-based chemoradiotherapy may be considered in defined high-risk or non-surgical settings, but cisplatin requires renal assessment, hydration, electrolyte monitoring, antiemetic prophylaxis, hearing and neuropathy review and careful management of interacting nephrotoxins. Alternative radiosensitising or systemic approaches are not automatically equivalent and should follow a documented oncology protocol. Doses, schedules and eligibility must not be inferred from this guide.
Recurrent or metastatic squamous cancer may be treated with immunotherapy, chemotherapy, targeted treatment or combinations chosen according to biomarkers, prior exposure, disease tempo and local access. Immune checkpoint treatment can cause pneumonitis, hepatitis, colitis, endocrinopathy, nephritis and skin toxicity; new diarrhoea, dyspnoea, jaundice, profound fatigue or neurological change during or after treatment needs urgent oncology assessment. Cytotoxic therapy can cause febrile neutropenia, mucositis, renal injury and electrolyte disturbance. Fever in a recently treated patient is an emergency, not a reason to wait for the next clinic.
Supportive prescribing is equally important. Use a stepped analgesic plan with constipation and nausea prevention where opioids are used. Treat oral candidiasis only when clinically supported. Mucositis care includes meticulous oral hygiene, hydration, nutrition and protocol-based analgesia; routine unverified mixtures may worsen irritation or obscure toxicity. Review swallowing safety before tablets or thin liquids. Radiotherapy patients need dental planning before exposure, fluoride and long-term jaw precautions. Herbal and over-the-counter products should be documented because interactions and mucosal injury are possible. All prescribing remains under the treating Indian team's current formulary and monitoring standards.
When to Refer
Use urgent specialist referral for an unexplained oral ulcer lasting more than three weeks or a persistent unexplained neck lump, consistent with current guidelines. A lump on the lip or within the oral cavity, or an erythroplakic or erythroleukoplakic patch, warrants urgent dental or oral-cancer assessment; referral must not be delayed while repeated courses of antibiotics, antifungals or topical steroids are tried. The National Health Mission pathway uses a shorter two-week non-healing lesion trigger within community screening. These thresholds arise from different systems: neither means that a lesion is safe on day 20, and clinical concern can justify earlier referral.
Refer directly to a head-and-neck or oral-oncology service when there is induration, fixation, unexplained bleeding, progressive trismus, reduced tongue mobility, numb chin, cranial neuropathy, unexplained tooth mobility, mandibular or maxillary destruction, or a suspicious cervical node. A person with a positive screening examination still needs diagnostic assessment; a community screen is not a cancer diagnosis. A potentially malignant disorder with dysplasia, a non-homogeneous or enlarging lesion, or persistent oral submucous fibrosis symptoms needs specialist risk stratification and surveillance.
Escalate same day for threatened airway, uncontrolled oral haemorrhage, inability to swallow saliva, severe dehydration, aspiration, rapidly progressive facial or neck swelling, sepsis, or fever after systemic anticancer therapy. Once cancer is confirmed, refer early for dental optimisation, dietetics, speech and swallowing assessment, cessation support, psychosocial help and financial navigation. Re-referral is required for new ulceration, neck mass, weight loss or functional deterioration during surveillance, even after a previously reassuring appointment.
Red Flags
Red flags reflect danger or high cancer probability, not a checklist that must be complete. A persistent indurated ulcer, especially on the lateral tongue or floor of mouth, unexplained erythroplakia, a mixed red-white lesion, an enlarging oral mass or a firm cervical node should prompt urgent action. Additional concerning findings include spontaneous bleeding, fixation to deep tissues, progressive pain or referred ear pain, trismus, reduced tongue movement, dysarthria, dysphagia, odynophagia, numbness in the mental-nerve distribution, unexplained loose teeth, ill-fitting dentures caused by tissue change, exposed destructive bone and weight loss. Lack of pain is not reassuring.
Airway noise, stridor, drooling, inability to handle secretions, brisk bleeding, syncope or rapidly expanding swelling are emergency features. Severe malnutrition and dehydration may be less dramatic but can make treatment unsafe. During therapy, fever or rigors after chemotherapy, uncontrolled vomiting, reduced urine output, confusion, severe mucositis preventing fluids, new breathlessness, neck swelling or bleeding requires urgent oncology or emergency evaluation. After reconstruction, flap colour change, rapidly increasing pain, wound bleeding or sudden swelling needs immediate surgical review.
After radiotherapy, new exposed jaw bone, pathological fracture, severe dental infection or progressive swallowing impairment requires specialist assessment; traumatic extraction in an irradiated field can carry added risk. Recurrence may present as subtle induration, persistent pain, a new neck node or deteriorating function rather than a large visible lesion. Safety-net every apparently benign lesion with a documented review date and escalation criteria. A negative image, an initial superficial benign biopsy or improvement in inflammation must be reconsidered when clinical and pathological findings do not agree.
Indian Clinical Context
India's oral-cancer pathway begins with prevention and visible-site detection but must not stop at screening. The National Health Mission operational guidance integrates risk assessment and oral screening for men and women over 30 into primary-care activity and directs people with a non-healing oral ulcer, patch or growth to medical review. This creates an opportunity to ask specifically about bidi smoking, smokeless tobacco and areca or betel preparations, inspect the full mouth and connect a screen-positive person to biopsy. Programme targets and paper referral slips are not outcomes; systems should track whether pathology, staging and treatment actually occurred.
Access varies. A village screening camp, dental clinic, district hospital and comprehensive cancer centre have different equipment and expertise. The first clinician should photograph or diagram the lesion where consent and information governance permit, document risk products precisely, assess nutrition and ensure a named referral destination. Travel cost, loss of wages, stigma, language, dependence and fear of disfigurement commonly interrupt care. Navigation, tobacco-dependence treatment, family counselling and early reconstructive explanation can reduce avoidable loss to follow-up.
Indian practice should use local pathology quality, imaging access, tumour-board protocols, essential-medicine availability and state funding mechanisms. current guidelines recommendations assume UK suspected-cancer timelines and concentrated services; NCI PDQ describes evidence, not an Indian standard. Neither source authorises importing a regimen without confirming Indian approvals, formulation access and monitoring capacity. GLOBOCAN values are modelled estimates and should not be described as registry-confirmed national totals. Opportunistic or population screening also does not justify random biopsy of every benign variant; it requires trained examination, defined referral and audit of completion.
NMC Competency Mapping
The 2024 National Medical Commission curriculum gives oral cancer explicit undergraduate anchors across pathology and surgery. PA23.1 requires the learner to describe the aetiology, pathogenesis, pathology and clinical features of oral cancers. SU20.1 addresses etiopathogenesis, symptoms and signs of oral and oropharyngeal cancer, while SU20.2 requires appropriate investigations and principles of treatment. The wording combines oral and oropharyngeal teaching at one surgical topic, but competent clinical reasoning must still preserve their anatomical, HPV and staging differences. The guide therefore supports, but does not replace, supervised clinical teaching against those competencies.
A learner meeting these outcomes should be able to take a tobacco, areca, alcohol and functional history; examine the oral subsites and cervical nodes; recognise leukoplakia, erythroplakia, submucous fibrosis and invasive features; and explain why biopsy establishes histology while imaging determines extent. They should distinguish incisional biopsy of a primary lesion from ultrasound-guided sampling of a node and understand the contributions of CT, MRI and systemic staging. They should describe depth of invasion, nodal metastasis, extranodal extension and margin status without attempting independent stage assignment from incomplete information.
Management knowledge includes the role of surgery, neck treatment, reconstruction, radiotherapy, systemic radiosensitisation, nutrition, dental care, speech and swallowing rehabilitation, cessation and palliation. Assessment can use a structured oral examination, case presentation, pathology discussion and tumour-board plan. Students should not practise unsupervised biopsy, promise a specific operation or prescribe chemotherapy. Communication outcomes include explaining uncertainty, avoiding stigma about tobacco use, obtaining consent for examination and safety-netting a lesion that has not healed.
Key Exam Pearls for NEET PG
First, define the site. The anterior two-thirds of tongue belongs to oral cavity; the tongue base belongs to oropharynx. Do not automatically apply HPV-associated oropharyngeal staging or prognosis to an oral-tongue squamous carcinoma. Common oral subsites have predictable cervical drainage, but midline proximity can create bilateral risk. A neck examination is mandatory even when the oral lesion appears small. Histological diagnosis precedes definitive treatment, and a suspicious node may be sampled under ultrasound guidance rather than excised casually.
In current oral-cavity TNM reasoning, depth of invasion is not the same as gross tumour thickness and changes T categorisation. Extranodal extension materially affects nodal staging and postoperative risk. Superficial erosion of a tooth socket alone is not automatically equivalent to advanced cortical invasion. Surgical margins, perineural invasion, lymphovascular invasion, T category, number and level of nodes and extranodal extension help determine adjuvant treatment. Early N0 oral-cavity cancer still needs a deliberate neck strategy; observation is not the default inference from a clinically impalpable neck.
Erythroplakia generally deserves more concern than a homogeneous white patch, but neither colour establishes dysplasia. Oral submucous fibrosis is associated with areca use and presents with mucosal stiffness and reduced mouth opening. Field exposure creates risk of second primary upper-aerodigestive tumours, so cessation and surveillance remain important after cure. For vignettes, prioritise an unexplained ulcer lasting over three weeks, persistent neck lump, progressive trismus, tongue restriction, induration or numb chin for urgent referral. Never let a temporary response to antibiotics overrule a persistent structural lesion.
Frequently Asked Questions
Does every white patch in the mouth become oral cancer?
No. A white patch has many possible causes, and leukoplakia is a clinical diagnosis of exclusion rather than a cancer diagnosis. Risk depends on the lesion's site, texture, pattern, size, evolution and histology. A persistent, non-homogeneous or unexplained patch still needs trained assessment and sometimes biopsy; appearance alone cannot prove safety.
Can a sharp tooth explain a mouth ulcer without further testing?
A sharp tooth or denture can cause trauma, but that explanation must be tested by removing the irritant and documenting healing. Induration, progression, a neck node or persistence beyond the expected interval requires urgent assessment. Repeatedly attributing a non-healing lesion to trauma without review is a recognised route to delayed diagnosis.
Is oral cancer always caused by smoking tobacco?
No. Smoking is an important risk, but smokeless tobacco, areca or betel preparations and alcohol are also relevant, and some patients report none of them. A person without a recognised exposure can still develop oral cancer. Risk history guides prevention and suspicion; it must never be used to deny biopsy of a concerning lesion.
Why may treatment include surgery on the neck when no node is felt?
Microscopic nodal metastases can exist in a clinically N0 neck, and their probability depends on the primary tumour and depth of invasion. Current guidelines recommends a planned surgical neck strategy for early oral-cavity cancer, with sentinel-node biopsy available in selected patients. The treating team chooses the approach using imaging, pathology, expertise and reconstructive needs.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic